WASHINGTON, D.C. — The Department of Veterans Affairs said pharmaceutical price reductions have reached a record $10.44 billion so far in fiscal 2026, nearly double the $5.23 billion achieved in fiscal 2024 and extending a sharp increase in negotiated savings under the Trump administration.
VA reported $7.99 billion in pharmaceutical price reductions in fiscal 2025 before reaching $10.44 billion in the current fiscal year to date.
The department said the gains reflect a broader effort to negotiate lower prices on medicines it purchases most frequently for veterans. Lower acquisition costs can allow VA to stretch pharmaceutical spending across more patients and preserve resources for newer therapies that often carry higher prices early in their commercial life.
The agency did not provide additional detail in the release on which drugs or manufacturers accounted for the largest reductions, nor did it specify how much of the fiscal 2026 total reflects newly negotiated discounts versus continuing savings from prior agreements.
“Under President Trump, VA is racking up huge wins for Veterans and taxpayers by demanding a better deal from pharmaceutical companies,” VA Secretary Doug Collins stated.
The department characterized the fiscal 2026 figure as the highest level of pharmaceutical price reductions it has recorded.
VA’s reported savings trajectory has risen from $5.23 billion in fiscal 2024 to $7.99 billion in fiscal 2025 and $10.44 billion so far in fiscal 2026, representing increases of about 53% and 31%, respectively, across those reporting periods.
Because fiscal 2026 remains in progress, the current total is not directly comparable with a completed full-year figure without accounting for the remaining months of the fiscal year.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.